Please login to the form below

Not currently logged in
Email:
Password:

Zosano appoints Chris Krueger as chief business officer

He joins from Ardea Biosciences

Chris Kruger has joined Zosano Pharma as chief business officer.

He joins the US-based biopharma from Ardea Biosciences, where he served as senior VP and chief business officer.

During his time at Ardea, Krueger completed a $407m global partnership with Bayer HealthCare.

In his new role, he will be responsible for business development, legal, and investor relations activities of Zosano as it prepares to expand its efforts in developing drug's utilising its novel drug delivery system.

Additional previous roles Krueger has held include senior executive positions at Protemix, Xencor, X–Ceptor Therapeutics and Aurora Biosciences.

His experience includes a broad range of transactions, including licensing, strategic alliances, mergers and acquisitions and equity and debt financings.

"It's exciting for me to join the Zosano team as the company enters its next stage of corporate growth," said Krueger.

"With its novel transdermal drug delivery system, Zosano is poised to develop therapeutic products through its own efforts and through strategic collaborations."

12th April 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics